REG - Immupharma PLC - Total Voting Rights

ImmuPharmaAnnouncement

16/08/2022 08:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220816:nRSP0957Wa&default-theme=true

RNS Number : 0957W  Immupharma PLC  16 August 2022

RNS | 16 August 2022

ImmuPharma plc

Total Voting Rights

ImmuPharma plc ("ImmuPharma" or "the Company"), announces that further to the
announcements dated 3 August 2022 and 11 August 2022, the Subscription Shares,
Placing Shares, Value Payment Shares, Fee Shares and Broker Option Shares (all
as defined in the aforementioned announcements) have today been admitted to
trading on AIM.

Consequently, the Company's issued share capital now comprises, 327,403,115
Ordinary Shares with one voting right each and 284,984,933 deferred shares
with no rights to vote. As the Company does not hold any shares in treasury,
the total number of voting rights in the Company is also 327,403,115 and this
figure of Ordinary Shares may be used by shareholders as the denominator for
the calculations by which they will determine if they are required to notify
their interest in, or a change to their interest in, the share capital of the
Company under the FCA's Disclosure Guidance and Transparency Rules.

Ends

For further information, please contact:

 ImmuPharma PLC (www.immupharma.com (http://www.immupharma.com) )        + 44 (0) 207 152 4080

 Tim McCarthy, Chief Executive Officer & Chairman

 Lisa Baderoon, Head of Investor Relations & Non-Executive Director      + 44 (0) 7721 413496

 SPARK Advisory Partners Limited (NOMAD)                                 +44 (0) 203 368 3550

 Neil Baldwin

 Stanford Capital Partners (Joint Broker)                                +44 20 3650 3650

 Patrick Claridge, John Howes, Bob Pountney

 SI Capital (Joint Broker)                                               +44 (0) 1483 413500

 Nick Emerson

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TVRSFIESIEESEEA